RGLSUnknownSmall-Cap
Regulus Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Regulus Therapeutics Inc. (RGLS), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RGLS insiders buying or selling?
Regulus Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since November 2018, Trabud has recorded 74 Form 4 filings for RGLS: 38 buys ($45.0M) and 36 sells ($497.3K).
Source: SEC EDGAR Form 4
Key Statistics (November 2018 – Jun 4, 2025)
Total Form 4 filings
74
SEC EDGAR
Insider filers
23
Insider buys (38)
$45.0M
Insider sells (36)
$497.3K
Insider sentiment
Net buyingNet insider flow of $44.5M in net buying since November 2018.
Recent RGLS insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 4, 2025 | Preston Klassen | President & Head of R & D | Purchase | 12.0K | $7.99 | $95.9K | SEC ↗ |
| Jan 31, 2025 | Joseph P Hagan | Chief Executive Officer | Purchase | 50.0K | $1.09 | $54.3K | SEC ↗ |
| Jan 31, 2025 | David Baltimore | Director | Purchase | 19.6K | $1.06 | $20.8K | SEC ↗ |
| Jan 15, 2025 | Christopher Ray Aker | Sr. VP & General Counsel | Sale | 43.6K | $1.26 | $55.1K | SEC ↗ |
| Jan 15, 2025 | Joseph P Hagan | Chief Executive Officer | Sale | 127.1K | $1.26 | $160.5K | SEC ↗ |
| Jan 15, 2025 | Crispina Calsada | Chief Financial Officer | Sale | 43.8K | $1.26 | $55.3K | SEC ↗ |
| Jan 15, 2025 | Preston Klassen | President & Head of R & D | Sale | 31.4K | $1.26 | $39.7K | SEC ↗ |
| Jul 29, 2024 | Kathryn J Collier | Director | Purchase | 4.0K | $1.82 | $7.3K | SEC ↗ |
| Jan 19, 2024 | Crispina Calsada | Chief Financial Officer | Sale | 5.5K | $1.19 | $6.5K | SEC ↗ |
| Jan 19, 2024 | Christopher Ray Aker | Sr. VP & General Counsel | Sale | 5.5K | $1.19 | $6.5K | SEC ↗ |
| Jan 19, 2024 | Joseph P Hagan | Chief Executive Officer | Sale | 14.6K | $1.19 | $17.4K | SEC ↗ |
| Mar 1, 2022 | Denis Drygin | Chief Scientific Officer | Purchase | 76.7K | $0.23 | $17.6K | SEC ↗ |
| Feb 7, 2022 | Denis Drygin | Chief Scientific Officer | Purchase | 23.3K | $0.23 | $5.4K | SEC ↗ |
| Jan 26, 2022 | Joseph P Hagan | President and CEO | Purchase | 100.0K | $0.22 | $21.5K | SEC ↗ |
| May 17, 2021 | Joseph P Hagan | President and CEO | Sale | 4.2K | $0.89 | $3.7K | SEC ↗ |
| Apr 16, 2021 | Joseph P Hagan | President and CEO | Sale | 4.1K | $1.72 | $7.1K | SEC ↗ |
| Feb 17, 2021 | Christopher Ray Aker | Sr. VP & General Counsel | Sale | 828 | $1.72 | $1.4K | SEC ↗ |
| Feb 17, 2021 | Joseph P Hagan | President and CEO | Sale | 4.1K | $1.72 | $7.1K | SEC ↗ |
| Dec 7, 2020 | Paul Edward Walker | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Peter W. Sonsini | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Scott D Sandell | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Joshua Makower | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Mohamad Makhzoumi | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Anthony A. Florence Jr. | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
| Dec 7, 2020 | Carmen Chang | 10% Owner | Purchase | 4.4M | $0.62 | $2.7M | SEC ↗ |
Showing the 25 most recent of 74 Form 4 filings for Regulus Therapeutics Inc..
Most active RGLS insiders
- Joseph P Hagan19 filings
- Christopher Ray Aker14 filings
- Stelios Papadopoulos4 filings
- Daniel R. Chevallard3 filings
- Paul Edward Walker3 filings
Ask anything about RGLS insider activity
Use Trabud's AI agent to query Regulus Therapeutics Inc.'s Form 4 history in plain English — "Show me RGLS CEO purchases this year" or compare it against any other ticker.
Open the AI agentRGLS insider trading FAQ
Are Regulus Therapeutics Inc. insiders buying or selling?
Regulus Therapeutics Inc. insiders reported no open-market purchases or sales in the last 12 months. Since November 2018, Trabud has recorded 74 Form 4 filings for RGLS: 38 buys ($45.0M) and 36 sells ($497.3K). Over the full record that is net buying of $44.5M.
How many insiders trade RGLS stock?
23 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Regulus Therapeutics Inc.. The most recent filing was accepted on Jun 4, 2025.
Where does Trabud get RGLS insider trading data?
All RGLS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.